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How circulating signals of hunger and satiety enter the brain to reach neurons that govern energy balance
has long remained a matter of controversy and speculation. Balland et al. (2014) now elucidate molecular
mechanisms by which a highly specialized hypothalamic glial cell regulates transport of leptin across the
blood-brain barrier.Like the multiheaded dog Cerberus, pro-
tecting the entrance to Hades, and the
god of keys, Portunes, distinct compo-
nents of the blood-brain barrier (BBB)
permit or prevent the passage of specific
molecules such as leptin into and out
of the brain. Understanding the mecha-
nisms of regulated transport through
specific ‘‘gates’’ of the BBB represents
one of the key challenges of metabolism
research. In this issue, Balland and
colleagues report that specific glial cells
called tanycytes act as ‘‘gatekeepers’’
that regulate leptin’s entry into the hypo-
thalamus (Balland et al., 2014).
The regulation of energy homeostasis
relies on a highly responsive system in
which energy expenditure is exquisitely
balanced with nutrient intake to maintain
a constant body weight (Schwartz and
Porte, 2005). To achieve this, circulating
factors of hunger and satiety reflecting
nutrient availability must cross the BBB
to reach effector neurons. A defect in
this process invariably leads to uncon-
trolled body weight gain (Schwartz and
Porte, 2005 ). One circulating energy
indicator is leptin, an adipose-derived
hormone that normally enters the brain
to promote decreased food intake and
increased energy expenditure (Myers
et al., 2009). Obesity, however, leads to
a state of ‘‘leptin resistance,’’ in which a
large amount of circulating leptin fails to
regulate body weight. The mechanism
of leptin resistance may encompass a
defect in both leptin entry and action in
mediobasal hypothalamus (MBH) target
neurons (Banks, 2008; Kalra, 2008).
Indeed, in obese animals, leptin delivered
centrally through intracerebroventricularinjection (ICV) activates hypothalamic
neurons but is ineffective when given
peripherally.
The median eminence (ME), a BBB
structure located at the bottom of the third
ventricles, is uniquely positioned to regu-
late the passage of blood-borne signals
to the cerebrospinal fluid (CSF) and
MBH neurons (Banks, 2008; Kalra,
2008). Abutting tight junctions in the third
ventricle (3rdV), tanycytes are specialized
glial cells that extend from the 3rdV to
a plexus of permeable fenestrated capil-
laries, representing the first rampart
between blood and CSF (Mullier et al.,
2010) (Figure 1). Previously, Prevot and
colleagues showed that tanycytes regu-
late BBB plasticity according to nutrient
status by releasing vascular endothelial
growth factor A (VEGF-A) to endothelial
cells (Langlet et al., 2013). Now the
same group shows that tanycytes are
the ‘‘gatekeepers’’ that regulate leptin’s
entry into the hypothalamus.
Balland and colleagues first dissected
the kinetics by which peripheral leptin
enters the brain. Following the phosphor-
ylation of the transcription factor and
leptin effector STAT3, leptin’s signaling
cascade begins with tanycytes in the
ME and then transitions to hypothalamic
neurons. This sequence of events was
confirmed using Western blot analysis of
leptin content in the ME and the MBH,
which were microdissected at different
time points after peripheral injection. In
animals rendered obese with high-fat
feeding (DIO), leptin still accumulated in
the ME but failed to appear in the MBH,
suggesting that DIO disrupted the leptin
signaling pathway and the coordinatedCell Metabolism 19release of leptin from the ME to the
MBH. This phenomenon could be re-
capitulated in db/db mice, lacking the
signaling-competent form of the leptin
receptor (LeptR), suggesting that the
integrity of the leptin signaling cascade
is required for proper distribution of leptin
from the ME to the MBH. Further, a leptin
antagonist that retains LepR binding
activity but has no signaling activity failed
to accumulate in the ME or MBH. STAT3
activation in MBH neurons following
peripheral injection of leptin could be
selectively dampened in the arcuate
nucleus, ventromedial hypothalamus,
and dorsomedial hypothalamus by ICV
delivery of leptin-neutralizing antibodies,
suggesting that blood-borne leptin has
to be routed through the CSF to access
MBH neurons.
Next, the authors dissected the mole-
cular pathway engaged in tanycyte regu-
lation of leptin transport. They found that
tanycytes express the mRNA encoding
all LepR isoforms, respond to leptin
treatment with STAT3, Akt and ERK acti-
vation, and are able to internalize leptin
through clathrin-coated vesicles. Intrigu-
ingly, inhibitors of the leptin-signaling
cascade failed to prevent leptin transport
by tanycytes, suggesting that although
tanycyte transport of leptin depends on
LepR, it is independent of the classical
LepR-signaling cascade. Furthermore,
once loaded with exogenous leptin, the
tanycytes progressively released leptin
into the medium in a process requiring
ERK pathway activation and involving
colchicine-sensitive intravesicular traf-
ficking. Indeed, ERK pathway activation
through epidermal growth factor (EGF), February 4, 2014 ª2014 Elsevier Inc. 173
Figure 1. Model Depicting the Control of Brain Leptin Entry by Tanycytes
The median eminence (ME) is a privileged region of the blood brain barrier (BBB) composed of fenestrated capillaries (red) and glial cells highly structured
with tight junctions (green) that regulate brain access to blood-borne molecules. Tanycytes (red and shown in inset) are specialized glial cells that extend a
‘‘foot’’ starting from the surface of the third ventricle (3rdV) to the fenestrated capillaries. Tanycytes represent the first rampart between blood and cerebrospinal
fluid (CSF).
Under physiological conditions, peripheral leptin is internalized by tanycytes through a LepR-dependent mechanism. Tanycytes, in turn, release leptin into the
CSF allowing leptin to reach energy-sensing target neurons in the mediobasal hypothalamus (MBH) and exert its catabolic/anabolic action. During diet-induced
obesity tanycytes ‘‘hold on’’ to leptin, reducing its access to MBH neurons. Activating the ERK pathway through EGF treatment ‘‘frees’’ leptin from tanycytes and
restores its access to hypothalamic target neurons.
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leptin translocation in db/db and DIO
mice, and daily injection of EGF in DIO
mice increased energy expenditure and
locomotor activity, precipitating weight
loss.
Altogether, Balland and colleagues pre-
sent an elegant study establishing tany-
cytes as the first gatekeepers through
which leptin has to pass prior to reaching174 Cell Metabolism 19, February 4, 2014 ª2neurons and exerting its catabolic action.
In addition to identifying the BBB doors,
the authors provide us with a potential
key to unlock tanycytes through the acti-
vation of the ERK pathway. Although this
work has enormous clinical potential
for treating leptin resistance associated
with obesity, it needs to be confirmed in
humans, as most of the aforementioned
studies were performed in rodents.014 Elsevier Inc.Furthermore, it is unlikely that EGF treat-
ment can be a sustainable strategy for
human treatment given its promitotic ef-
fects. In addition, manipulating tanycyte
permeability may compromise brain pro-
tection and lead to ‘‘leakage’’ of poten-
tially dangerous molecules gathered into
the BBB from the bloodstream.
The results also raise several questions
for future investigations. What is the role
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other circumventricular organs such as
the area postrema? Do tanycytes regulate
the transport of other signals such as
ghrelin or nutrients? What role do tany-
cytes play in other mechanisms that
have been described to promote leptin
resistance such as ER stress, inflamma-
tion, or nutrient overload (Banks et al.,
2004; Milanski et al., 2009; Ozcan et al.,
2009)?
Finally, once their function as hypo-
thalamic gatekeepers is established the
question remains whether tanycytes are
amenable like Portunes, allowing targeted
pharmacology to manipulate leptin entry,or more like Cerberus, refusing any
negotiation.
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Macrophages in atherosclerotic plaques are activated, inflammatory cells that directly contribute to the
disease process. De Nardo et al. (2013), now report that high-density lipoproteins (HDL) can reprogram
macrophages to be less inflammatory through an ATF3-dependent pathway, providing another mechanistic
basis for the atheroprotective properties of HDL.Atherosclerosis is commonly referred
to as an inflammatory disease. The key
player in the early phase of inflammation
in plaques is the foot soldier of the innate
immune system, the macrophage. These
cells become activated in the arterial
wall in response to uptake of lipoproteins
containing apolipoprotein B, such as
low- and very-low-density lipoproteins
(LDLs and VLDLs) (Tabas et al., 2007).
The cholesterol carried by these lipopro-
teins causes themacrophages to become
engorged ‘‘foam cells,’’ which become
trapped in the arterial intima, establishing
the inflammatory milieu of the plaque. The
failure to resolve this inflammation is
thought to culminate in ‘‘vulnerable’’
atherosclerotic plaques, which are prone
to rupture, leading to heart attacks and
strokes. Inflammatory mediators (IL-1b,
TNFa, and MCP-1, etc.) secreted by
macrophage foam cells following thestimulation of innate immune receptors
such as Toll-like receptors (TLR), or via in-
flammasome pathways, have adverse
effects on the other two major cell types
in the plaques, endothelial and vascular
smooth muscle cells. Furthermore, dying
macrophage foam cells contribute to
the formation of the necrotic core, which
is enriched in cholesterol, inflammatory
substances, and thrombogenic Tissue
Factor and is a hallmark of vulnerable
plaques. Thus, factors that either impede
the escalating inflammation process or
reverse it may make it possible to derail
the march to a clinical event. It is in this
context that the studies by Latz and col-
leagues fall, by showing how HDL may
be a fire prevention or extinguishing agent
through stimulating an anti-inflammatory
pathway in macrophages that is depen-
dent on the transcription factor ATF3
(De Nardo et al., 2013).De Nardo et al. began by investigating
the effects of HDL on the activation of
macrophages by TLRs in vitro. First, they
confirmed previous studies (e.g., Yvan-
Charvet et al., 2008) showing that HDL
treatment reduced the inflammatory
responsiveness of the macrophages to
TLR stimulation. For this purpose, they
focused on TLR1, TLR2, and TLR9 (cho-
sen because they had been implicated in
previous studies in atherosclerotic mice),
using accepted ligands for each. They
found that the anti-inflammatory effects
of HDL were independent of HDL binding
of TLR ligands and did not involve the
classical early signaling downstream of
the TLRs. They also found in contrast
to Yvan-Charvet et al. (2008) that there
was no evidence that the impaired
TLR responsiveness resulted from HDL-
mediated depletion of cholesterol from
plasma and endosomal membranes., February 4, 2014 ª2014 Elsevier Inc. 175
